A Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Darunavir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 06 Oct 2016 Primary endpoint (Percentage of participants with HIV-1 RNA < 50 copies/mL at week 24 using the US FDA-defined snapshot algorithm-full analysis set), has been met.
- 06 Oct 2016 Results of this study, published in the Journal of Acquired Immune Deficiency Syndromes (JAIDS).
- 24 Jun 2016 Status changed from active, no longer recruiting to completed.